US2016144007A1PendingUtilityA1

Treatment of conditions related to shock

59
Assignee: UNIV CALIFORNIAPriority: Oct 4, 2007Filed: Jan 29, 2016Published: May 26, 2016
Est. expiryOct 4, 2027(~1.2 yrs left)· nominal 20-yr term from priority
Inventors:Geert W. Schmid-SchoenbeinFrank A. Delano
A61K 31/4164A61P 31/00A61K 31/195A61P 43/00A61K 45/06A61K 31/496A61K 31/201A61K 31/24A61K 31/431A61K 38/38A61K 38/57A61K 31/424A61K 31/407A61K 31/546A61K 31/197A61K 31/65A61K 31/337A61P 5/50
59
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Techniques are disclosed for prevention or treatment of physiological shock by administering a specific therapeutic agent, which is able to use smaller volumes of reagent to achieve complete inhibition, than other previously described techniques.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A method for reducing insulin resistance in physiological shock comprising:
 administering to a peritoneum of an individual a therapeutic dose of any combination of one or more of: pancreatic digestive enzyme inhibitor, cytotoxic mediator inhibitor, and antibacterial agent.   
     
     
         2 . The method of  claim 1 , further comprising administering to the individual a therapeutic dose of a MMP inhibitor. 
     
     
         3 . The method of  claim 2 , wherein the MMP inhibitor includes doxycycline. 
     
     
         4 . The method of  claim 2 , wherein the MMP inhibitor is administered through an i.v. 
     
     
         5 . The method of  claim 2 , wherein the MMP inhibitor is administered directly into the lumen of the intestine. 
     
     
         6 . The method of  claim 1 , further comprising administering to an intestine of the individual a therapeutic dose of one or more of: serine protease inhibitor and lipase inhibitor. 
     
     
         7 . A method for reducing mortality after shock, the method comprising:
 administering to a peritoneum of an individual a therapeutic dose of any combination of one or more of: pancreatic digestive enzyme inhibitor, cytotoxic mediator inhibitor, and antibacterial agent.   
     
     
         8 . The method of  claim 7 , further comprising administering to the individual a therapeutic dose of a MMP inhibitor. 
     
     
         9 . The method of  claim 7 , further comprising administering to an intestine of the individual a therapeutic dose of one or more of: a serine protease inhibitor and a lipase inhibitor. 
     
     
         10 . A method for prevention of organ fusion in the peritoneum, the method comprising:
 administering to the peritoneum of an individual a therapeutic dose of any combination of one or more of: pancreatic digestive enzyme inhibitor, cytotoxic mediator inhibitor, and antibacterial agent.   
     
     
         11 . The method of  claim 10 , further comprising administering to the individual a therapeutic dose of a MMP inhibitor. 
     
     
         12 . The method of  claim 10 , further comprising administering to an intestine of the individual a therapeutic dose of one or more of: a serine protease inhibitor and a lipase inhibitor. 
     
     
         13 . A method for prevention of organ fusion, the method comprising:
 administering a therapeutic dose of any combination of one or more of: pancreatic digestive enzyme inhibitor, cytotoxic mediator inhibitor, and antibacterial agent.   
     
     
         14 . The method of  claim 13 , further comprising administering to the individual a therapeutic dose of a MMP inhibitor. 
     
     
         15 . The method of  claim 13 , further comprising administering a therapeutic dose of one or more of: a serine protease inhibitor and a lipase inhibitor. 
     
     
         16 . The method of  claim 13 , wherein the administering takes place in the intercostal space. 
     
     
         17 . The method of  claim 13 , wherein the administering takes place in the pericardium.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.